Ask the Expert: Avastin for Recurrent Glioblastoma Multiforme

What is Avastin?

Avastin® (Bevacizumab) is the first and only biologic treatment approved by Health Canada for recurrent glioblastoma multiforme (GBM), which offers an additional treatment option for people with the disease.

How is Avastin administered?

Avastin is given as a single agent at 10 mg/kg intravenously, once every two weeks.

How does Avastin work?

Avastin directly targets the tumour by controlling its growth and extends survival with only a limited impact on quality of life.

Is Avastin approved by Health Canada?

Health Canada approved Avastin in March 2010 as treatment for recurrent GBM.

How do patients access Avastin?

The answer to this question depends on:

  • The province in which the patient lives: In British Columbia, Saskatchewan and Manitoba, there is public access for Avastin in recurrent GBM via provincial drug plans.
  • Whether the patient has private insurance that provides coverage for Avastin.

Beyond the provinces where there is provincial coverage, access to Avastin depends on the type of private insurance coverage each patient may have (often from an employer). Once prescribed Avastin by their oncologist, a patient will contact their insurance carrier to determine coverage.

Please note, however, reimbursement via private insurance coverage is often granted on a case-by-case basis and may not be guaranteed.

There is also a Roche Patient Assistance Program (RPAP) in place to help patients access Avastin.

How do patients connect with the RPAP program?

For reimbursement navigation and coordination, financial assistance and infusion support services, patients should work with their oncologist to enrol in RPAP or call the program directly, toll-free, at 1-888-748-8926, Monday to Friday, 8:00 am to 8:00 pm Eastern Standard Time. Patients can also visit the RPAP website for more information.

Find more information about how to access Avastin

What is the most recent information about Avastin?

New research about the brain tumour treatment Bevacizumab (Avastin®) was released at the recent American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. Results were presented from two recent clinical trials focused on the treatment. Read our summary of the results.

Find more information about advocacy on behalf of a patient or advocacy in support of the brain tumour community in the advocacy section of the website.
Download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf)

Return to Information Sheets here.

This information is provided for information purposes only, and do not represent advice, an endorsement or a recommendation, with respect to any product, service or business, and/or the claims and properties thereof, by Brain Tumour Foundation of Canada. Always consult your health care team if you have questions about your medical care and treatments options.

Share This

Featured Story

Ellen's Story and The Courageous Lion

Friendships often start when least expected, but for Ellen Erenberg, a professional artist and art instructor, the bond she formed with Erin Voss was unmistakeable. Read more about the friendship and how The Courageous Lion came to be.

Learn more

Spotlight

Rick's Story: Find the Help You Need and Deserve

When an odd stroke of luck ended up with Winnipeg firefighter Rick Negrich getting a CT scan, the last thing he expected was to be...

Learn more

Meet Patrick

Patrick's story update: Read about the incredible gift he received this Christmas!...

Learn more

Upcoming Events

  • 15/Feb/2016: Guelph Support Group: Meets at Hospice Wellington, Community Program Room, 795 Scottsdale Avenue,... Learn more >
  • 15/Feb/2016: Edmonton Support Group: Meets at Zion Lutheran Church, 11533-135 Street in Edmonton ... Learn more >
  • 15/Feb/2016: New Glasgow Support Group: Meets at East Haven Manor, 695 East River Road in New Glasgow, NS ... Learn more >
  • 16/Feb/2016: Virtual Support Group West: Virtual Support Group for Western Canada... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2016 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
Imagine Canada Ethical Code